×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALIM – alimera sciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALIM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/25
Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference
26.0%
11/13 Alimera Sciences Terminates Equity Purchase Agreement 19.8%
4/13 Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update 18.1%
2/26 Q4/2019 12/31/2019 EPS 0.080 ZacksConsensus -0.370 ActVsEst 0.450 - Beat 14.7%
9/11 Alimera Sciences Inc (NASDAQ: ALIM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 12.9%
3/31 Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement 10.8%
11/8 Form 8-K ALIMERA SCIENCES INC For: Nov 07 10.5%
11/14 Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split 9.0%
11/15 Alimera Sciences Inc (NASDAQ: ALIM) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 8.3%
10/14 Alimera Sciences Inc (NASDAQ: ALIM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.0%
11/13 Alimera Sciences Terminates Equity Purchase Agreement 19.8%
4/13 Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update 18.1%
2/26 Q4/2019 12/31/2019 EPS 0.080 ZacksConsensus -0.370 ActVsEst 0.450 - Beat 14.7%
9/11 Alimera Sciences Inc (NASDAQ: ALIM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 12.9%
3/31 Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement 10.8%
11/8 Form 8-K ALIMERA SCIENCES INC For: Nov 07 10.5%
11/14 Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split 9.0%
11/15 Alimera Sciences Inc (NASDAQ: ALIM) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 8.3%
10/14 Alimera Sciences Inc (NASDAQ: ALIM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.0%
TOP News Decliners
7/29
Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update
-31.6%
7/30 Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -23.8%
3/11 Form 4 ALIMERA SCIENCES INC For: Mar 09 Filed by: Kaba Samer -23.1%
6/20 Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis -16.4%
11/13 Form 8-K ALIMERA SCIENCES INC For: Nov 12 -16.1%
3/18 Form SEC STAFF LETTER ALIMERA SCIENCES INC -14.3%
10/1 Alimera Sciences Inc (NASDAQ: ALIM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -13.7%
10/1 Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting -13.5%
11/7 Form 8-K/A ALIMERA SCIENCES INC For: Nov 04 -12.7%
9/3 Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication -11.6%
7/30 Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -23.8%
3/11 Form 4 ALIMERA SCIENCES INC For: Mar 09 Filed by: Kaba Samer -23.1%
6/20 Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis -16.4%
11/13 Form 8-K ALIMERA SCIENCES INC For: Nov 12 -16.1%
3/18 Form SEC STAFF LETTER ALIMERA SCIENCES INC -14.3%
10/1 Alimera Sciences Inc (NASDAQ: ALIM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -13.7%
10/1 Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting -13.5%
11/7 Form 8-K/A ALIMERA SCIENCES INC For: Nov 04 -12.7%
9/3 Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication -11.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: